The hypothalamic control of bone mass, implication for the treatment of osteoporosis.
Karsenty
G
G
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030, USA.
Ducy
P
P
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D015519:Bone Density / Q000502:physiology*; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D007031:Hypothalamus / Q000503:physiopathology*; D020738:Leptin / Q000502:physiology; D010024:Osteoporosis / Q000628:therapy*; D015663:Osteoporosis, Postmenopausal; D018343:Receptors, Adrenergic, beta-2 / Q000502:physiology
D000319:Adrenergic beta-Antagonists; D020738:Leptin; D018343:Receptors, Adrenergic, beta-2